SANA

SEC source: 0001480212-26-000010 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,863,480

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0002115339-26-000004 · primarydocument.xml · nonDerivative · entry 2

PATEL DHAVALKUMAR DHIRAJLAL · CIK 0002115339 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,352

SEC source: 0002115339-26-000004 · primarydocument.xml · derivative · entry 3

PATEL DHAVALKUMAR DHIRAJLAL · CIK 0002115339 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 125,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0002115339-26-000004 · primarydocument.xml · nonDerivative · entry 1

PATEL DHAVALKUMAR DHIRAJLAL · CIK 0002115339 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001480212-26-000008 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,854,800

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001612312-26-000002 · primarydocument.xml · derivative · entry 1

Bilenker Joshua H. · CIK 0001612312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001480212-26-000006 · primarydocument.xml · derivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001770121-26-000003 · primary_doc.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date

SEC source: 0001309988-26-000002 · primarydocument.xml · derivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001376247-26-000002 · primarydocument.xml · derivative · entry 1

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001645041-26-000002 · primarydocument.xml · derivative · entry 1

Rosiello Robert L. · CIK 0001645041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001757533-26-000011 · primarydocument.xml · derivative · entry 1

REICIN ALISE · CIK 0001757533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001836301-26-000014 · primarydocument.xml · derivative · entry 1

Seitz Michelle · CIK 0001836301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001480212-26-000004 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,848,503

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 4

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,196

SEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,241

SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 4

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,944,251

SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 3

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,957,070

SEC source: 0001568605-26-000008 · primarydocument.xml · derivative · entry 6

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 3,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F3 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F3 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001627387-26-000004 · primarydocument.xml · derivative · entry 9

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F4 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F4 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 2

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,968,596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001568605-26-000008 · primarydocument.xml · derivative · entry 5

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,251

Underlying: Common Stock · 10,416 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001627387-26-000004 · primarydocument.xml · derivative · entry 8

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,001

Underlying: Common Stock · 41,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F3 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F3 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 1

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,918,596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001568605-26-000006 · primarydocument.xml · derivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,250

Underlying: Common Stock · 206,250 shares

Expires 2036-03-04

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001568605-26-000006 · primarydocument.xml · derivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,833

Underlying: Common Stock · 45,833 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001627387-26-000002 · primarydocument.xml · derivative · entry 2

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2036-03-04

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001627387-26-000002 · primarydocument.xml · derivative · entry 1

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001568605-26-000004 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,917

SEC source: 0001568605-26-000004 · primarydocument.xml · derivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,525

Underlying: Common Stock · 1,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001568605-26-000004 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001665924-26-000008 · primarydocument.xml · derivative · entry 2

Piper Brian · CIK 0001665924 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2036-02-16

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on February 17, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001665924-26-000008 · primarydocument.xml · derivative · entry 1

Piper Brian · CIK 0001665924 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001480212-26-000002 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,840,740

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001568605-26-000002 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,883

SEC source: 0001568605-26-000002 · primarydocument.xml · derivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

F2 · derivative.exercise_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026.

F2 · derivative.expiration_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026.

SEC source: 0001568605-26-000002 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,290

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001568605-25-000007 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,790

SEC source: 0001568605-25-000007 · primarydocument.xml · derivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

F2 · derivative.exercise_date: The award vested as to 100% of the restricted stock units on December 13, 2025.

F2 · derivative.expiration_date: The award vested as to 100% of the restricted stock units on December 13, 2025.

SEC source: 0001568605-25-000007 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,663

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 4

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,263

SEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 8

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

F7 · derivative.exercise_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.

F7 · derivative.expiration_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.

SEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,828

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · balance_after: Includes 3,000 shares acquired on November 14, 2025 pursuant to the ESPP.

SEC source: 0001480212-25-000006 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,834,583

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-25-005349 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,828,955

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-25-004640 · primarydocument.xml · derivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-25-004646 · primarydocument.xml · derivative · entry 1

Bilenker Joshua H. · CIK 0001612312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-25-004645 · primarydocument.xml · derivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.